Dyslipidemia and lower extremity arterial disease

被引：0

作者：

Paraskevas, Kosmas I. ^{[1
]}

Poredos, Pavel ^{[2
]}

Stanek, Agata ^{[3
,4
]}

Blinc, Ales ^{[2
,5
]}

Jawien, Arkadiusz ^{[6
]}

Antignani, Pier Luigi ^{[7
]}

Mansilha, Armando ^{[8
]}

Mikhailidis, Dimitri P. ^{[9
,10
]}

机构：

[1] Red Cross Hosp, Dept Vasc Surg, 24 Alex Papagou St, Athens 14122, Greece

[2] Univ Med Ctr Ljubljana, Dept Vasc Dis, Ljubljana, Slovenia

[3] Med Univ Silesia, Fac Med Sci Zabrze, Dept Internal Med Angiol & Phys Med, Bytom, Poland

[4] Med Univ Silesia, Clin Internal Med Angiol & Phys Med, Fac Med Sci Zabrze, Bytom, Poland

[5] Univ Ljubljana, Fac Med, Dept Internal Med, Ljubljana, Slovenia

[6] Nicolaus Copernicus Univ Torun, Dept Vasc Surg & Angiol, L Rydygier Coll Med Bydgoszcz, Torun, Poland

[7] Nuova Villa Claudia, Vasc Ctr, Rome, Italy

[8] Univ Porto, Hosp S Joao, Dept Angiol & Vasc Surg, Porto, Portugal

[9] Univ Coll London UCL, Univ Coll London Med Sch, Dept Surg Biotechnol, Div Surg & Intervent Sci, London, England

[10] Univ Coll London UCL, Royal Free Hosp Campus, Dept Clin Biochem, London, England

来源：

INTERNATIONAL ANGIOLOGY | 2024年

关键词：

Dyslipidemia; Peripheral arterial disease; Lower extremity arterial disease; Statins; Surgical amputation; AMPUTATION-FREE SURVIVAL; CRITICAL LIMB ISCHEMIA; STATIN THERAPY; LIPID MANAGEMENT; RISK-FACTORS; MORTALITY; CHOLESTEROL; OUTCOMES; ASSOCIATION; LIPOPROTEIN;

D O I：

10.23736/S0392-9590.24.05266-0

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Introduction: Dyslipidemia is an established risk factor for cardiovascular diseases. We aimed to review its role in the pathogenesis of lower extremity arterial disease (LEAD), as well as the effect of lipid-lowering treatment on the progression of LEAD. Evidence acquisition: PubMed/MedLine, EMBASE and Scopus were searched between January 1990 and January 2024 for articles investigating the role of dyslipidemias and hyperlipidemias in the pathogenesis of LEAD. A separate search focused on the effects of lipid-lowering therapy on patients with LEAD. Evidence synthesis: There is evidence that dyslipidemias play a major role in the development of LEAD. All patients with LEAD should receive intensive lipid-lowering therapy for the reduction not only of claudication symptoms and amputation rates, but also of myocardial infarction and cardiovascular event rates. Conclusions: Vascular specialists should keep in mind the pivotal role of dyslipidemia in the pathogenesis and progression of LEAD.

引用

页数：8

共 50 条

[1] Lower Extremity Arterial Disease
Maydick-Youngberg, Diane
WOUND MANAGEMENT & PREVENTION, 2021, 67 (02) : 19 - 20
[2] Lower extremity arterial disease in sports
Abraham, P
Chevalier, JM
Leftheriotis, G
Saumet, JL
AMERICAN JOURNAL OF SPORTS MEDICINE, 1997, 25 (04): : 581 - 584
[3] Lower extremity arterial disease (LEAD)
Espinola-Klein, Christine
HERZ, 2024, 49 (04) : 313 - 318
[4] Lower extremity peripheral arterial disease
Chung, Melissa Johnson
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2015, 28 (03): : 54 - 55
[5] The significance of lower extremity peripheral arterial disease
Dieter, RS
Chu, WW
Pacanowski, JP
McBride, PE
Tanke, TE
CLINICAL CARDIOLOGY, 2002, 25 (01) : 3 - 10
[6] Lower extremity arterial disease in patients with diabetes
Mohammedi, Kamel
Alexandre, Laure
Blanco-Baillet, Laurence
Rigalleau, Vincent
CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2018, 22 (3-4): : 69 - 74
[7] Management of Lower Extremity Peripheral Arterial Disease
Gardner, Andrew W.
Afaq, Azhar
JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION, 2008, 28 (06) : 349 - 357
[8] Hypothyroidism and the risk of lower extremity arterial disease
Mazzeffi, Michael A.
Lin, Hung-Mo
Flynn, Brigid C.
O'Connell, Thomas L.
DeLaet, David E.
VASCULAR HEALTH AND RISK MANAGEMENT, 2010, 6 : 957 - 962
[9] Treatment of Lower Extremity Peripheral Arterial Disease
Behrendt, Christian-Alexander
Koncar, Igor
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2024, 68 (03) : 288 - 289
[10] Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease
Meade, TW
CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2001, 2 (04): : 195 - 204

← 1 2 3 4 5 →